Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Immune Complexes and the Risk of CVD in Type 1 Diabetes.

Lopes-Virella MF, Bebu I, Hunt KJ, Virella G, Baker NL, Braffett B, Gao X, Lachin JM; DCCT/EDIC Research Group.

Diabetes. 2019 Sep;68(9):1853-1860. doi: 10.2337/db19-0358. Epub 2019 Jun 19.

PMID:
31217176
2.

Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Hammad SM, Arthur J, Virella G, Klein RL; DCCT/EDIC Research Group.

J Clin Lipidol. 2019 May - Jun;13(3):481-491.e1. doi: 10.1016/j.jacl.2019.03.005. Epub 2019 Apr 3.

PMID:
31043336
3.

Modified LDL Immune Complexes and Cardiovascular Disease.

Lopes-Virella MF, Virella G.

Curr Med Chem. 2019;26(9):1680-1692. doi: 10.2174/0929867325666180524114429. Review.

PMID:
29792135
4.

Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes.

Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Diabetes Care. 2018 Jan;41(1):128-135. doi: 10.2337/dc17-0867. Epub 2017 Nov 8.

5.

Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages.

Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella M.

Clin Immunol. 2018 Feb;187:1-9. doi: 10.1016/j.clim.2017.06.010. Epub 2017 Jul 8.

PMID:
28689783
6.

F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice.

Li Y, Lu Z, Huang Y, Lopes-Virella MF, Virella G.

Clin Immunol. 2016 Dec;173:50-56. doi: 10.1016/j.clim.2016.07.020. Epub 2016 Jul 22.

PMID:
27455858
7.

High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G; VADT Group of Investigators.

J Diabetes Complications. 2016 May-Jun;30(4):693-9. doi: 10.1016/j.jdiacomp.2016.01.012. Epub 2016 Jan 14.

PMID:
26861948
8.

Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort.

Hunt KJ, Baker NL, Cleary PA, Klein R, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators.

Diabetes Care. 2015 Jul;38(7):1281-9. doi: 10.2337/dc14-2877. Epub 2015 Apr 7.

9.

The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes.

Rajab HA, Baker NL, Hunt KJ, Klein R, Cleary PA, Lachin J, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators.

J Diabetes Complications. 2015 Jan-Feb;29(1):108-14. doi: 10.1016/j.jdiacomp.2014.08.004. Epub 2014 Aug 20.

10.

The role of the immune system in the pathogenesis of diabetic complications.

Virella G, Lopes-Virella MF.

Front Endocrinol (Lausanne). 2014 Jul 30;5:126. doi: 10.3389/fendo.2014.00126. eCollection 2014. No abstract available.

11.

Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes.

Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Metabolism. 2014 Oct;63(10):1287-95. doi: 10.1016/j.metabol.2014.07.001. Epub 2014 Jul 9.

12.

Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes.

Fu D, Yu JY, Wu M, Du M, Chen Y, Abdelsamie SA, Li Y, Chen J, Boulton ME, Ma JX, Lopes-Virella MF, Virella G, Lyons TJ.

J Lipid Res. 2014 May;55(5):860-9. doi: 10.1194/jlr.M045401. Epub 2014 Mar 10.

13.

Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2014 May;37(5):e108-9. doi: 10.2337/dc13-2976. Epub 2014 Feb 4. No abstract available.

14.

Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.

Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Atherosclerosis. 2013 Dec;231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027. Epub 2013 Oct 11.

15.

Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.

Lopes-Virella MF, Virella G.

J Atheroscler Thromb. 2013;20(10):743-54. Epub 2013 Aug 20. Review.

16.

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2013 Aug;36(8):2317-23. doi: 10.2337/dc12-2521. Epub 2013 Mar 20.

17.

Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes.

Virella G, Colglazier J, Chassereau C, Hunt KJ, Baker NL, Lopes-Virella MF.

J Immunoassay Immunochem. 2013;34(1):61-74. doi: 10.1080/15321819.2012.683500.

PMID:
23323982
18.

The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T; VADT Investigators.

Atherosclerosis. 2012 Oct;224(2):526-31. doi: 10.1016/j.atherosclerosis.2012.08.006. Epub 2012 Aug 21.

19.

The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.

Virella G, Lopes-Virella MF.

Front Endocrinol (Lausanne). 2012 Jun 15;3:76. doi: 10.3389/fendo.2012.00076. eCollection 2012.

20.

High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; DCCT/EDIC Study Group.

Diabetes Care. 2012 Jun;35(6):1333-40. doi: 10.2337/dc11-2040. Epub 2012 Apr 17.

21.

Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release.

Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM.

Immunology. 2012 May;136(1):30-45. doi: 10.1111/j.1365-2567.2012.03552.x.

22.

High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.

Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G; DCCT/EDIC Research Group.

Nephrol Dial Transplant. 2012 Apr;27(4):1416-23. doi: 10.1093/ndt/gfr454. Epub 2011 Aug 19.

23.

Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III.

Abdelsamie SA, Li Y, Huang Y, Lee MH, Klein RL, Virella G, Lopes-Virella MF.

Clin Immunol. 2011 Jun;139(3):258-66. doi: 10.1016/j.clim.2011.01.016. Epub 2011 Feb 10.

24.

Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G; DCCT/EDIC Research Group.

Atherosclerosis. 2011 Feb;214(2):462-7. doi: 10.1016/j.atherosclerosis.2010.11.012. Epub 2010 Nov 17.

25.

Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.

Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

Diabetes. 2011 Feb;60(2):582-9. doi: 10.2337/db10-0915. Epub 2010 Oct 27.

26.

Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress.

Al Gadban MM, Smith KJ, Soodavar F, Piansay C, Chassereau C, Twal WO, Klein RL, Virella G, Lopes-Virella MF, Hammad SM.

PLoS One. 2010 Sep 2;5(9). pii: e12534. doi: 10.1371/journal.pone.0012534.

27.

LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses.

Klein RL, Carter RE, Jenkins AJ, Lyons TJ, Baker NL, Gilbert GE, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

J Diabetes Complications. 2011 Mar-Apr;25(2):73-82. doi: 10.1016/j.jdiacomp.2010.03.001. Epub 2010 Jun 3.

28.

Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages.

Smith KJ, Twal WO, Soodavar F, Virella G, Lopes-Virella MF, Hammad SM.

J Biol Chem. 2010 May 21;285(21):15985-93. doi: 10.1074/jbc.M110.113605. Epub 2010 Mar 26.

29.

Immunology of cardiovascular disease.

Virella G.

Clin Immunol. 2010 Jan;134(1):1-4. doi: 10.1016/j.clim.2009.05.013. Epub 2009 Jun 16. No abstract available.

PMID:
19535296
30.

Clinical significance of the humoral immune response to modified LDL.

Lopes-Virella MF, Virella G.

Clin Immunol. 2010 Jan;134(1):55-65. doi: 10.1016/j.clim.2009.04.001. Epub 2009 May 8. Review.

31.

Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications.

Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G; Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group.

Diabetes Care. 2008 Oct;31(10):2006-12. doi: 10.2337/dc08-0659. Epub 2008 Jul 15.

32.

Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells.

Hammad SM, Twal WO, Barth JL, Smith KJ, Saad AF, Virella G, Argraves WS, Lopes-Virella MF.

Atherosclerosis. 2009 Feb;202(2):394-404. doi: 10.1016/j.atherosclerosis.2008.05.032. Epub 2008 May 28.

33.

Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Virella G, Carter RE, Saad A, Crosswell EG, Game BA; DCCT/EDIC Study Group, Lopes-Virella MF.

Clin Immunol. 2008 Jun;127(3):394-400.

34.

Atherogenesis and the humoral immune response to modified lipoproteins.

Virella G, Lopes-Virella MF.

Atherosclerosis. 2008 Oct;200(2):239-46. doi: 10.1016/j.atherosclerosis.2008.03.025. Epub 2008 Apr 12. Review.

35.

OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages.

Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF.

J Lipid Res. 2006 Sep;47(9):1975-83. Epub 2006 Jun 27.

36.

Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes.

Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G; DCCT/EDIC Research Group.

Atherosclerosis. 2007 Feb;190(2):359-69. Epub 2006 Mar 10.

PMID:
16530770
37.

Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort.

Yishak AA, Costacou T, Virella G, Zgibor J, Fried L, Walsh M, Evans RW, Lopes-Virella M, Kagan VE, Otvos J, Orchard TJ.

Nephrol Dial Transplant. 2006 Jan;21(1):93-100. Epub 2005 Sep 6.

PMID:
16144851
38.

The immunogenicity of modified lipoproteins.

Lopes-Virella MF, Thorpe SR, Derrick MB, Chassereau C, Virella G.

Ann N Y Acad Sci. 2005 Jun;1043:367-78. Review.

PMID:
16037258
39.

Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study.

Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ.

J Diabetes Complications. 2005 Jul-Aug;19(4):183-93.

PMID:
15993351
40.
41.

Development of capture assays for different modifications of human low-density lipoprotein.

Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF.

Clin Diagn Lab Immunol. 2005 Jan;12(1):68-75.

42.

Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies.

Virella G, Thorpe SR, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF.

J Lipid Res. 2004 Oct;45(10):1859-67. Epub 2004 Jul 16.

43.

Role of simvastatin as an immunomodulator in type 2 diabetes.

Lopes-Virella MF, Mironova M, Stephan E, Durazo-Arvizu R, Virella G.

Diabetes Care. 2004 Apr;27(4):908-13.

PMID:
15047647
44.

The role of immune and inflammatory processes in the development of macrovascular disease in diabetes.

Lopes-Virella MF, Virella G.

Front Biosci. 2003 Sep 1;8:s750-68. Review.

PMID:
12957881
45.

Lipoprotein autoantibodies: measurement and significance.

Virella G, Lopes-Virella MF.

Clin Diagn Lab Immunol. 2003 Jul;10(4):499-505. Review. No abstract available.

46.

LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1.

Fu Y, Huang Y, Bandyopadhyay S, Virella G, Lopes-Virella MF.

J Lipid Res. 2003 Jul;44(7):1315-21. Epub 2003 May 1.

47.

Humoral immunity and atherosclerosis.

Virella G, Lopes-Virella MF.

Nat Med. 2003 Mar;9(3):243-4; author reply 244-5. No abstract available.

PMID:
12612552
48.

Autoimmune response to advanced glycosylation end-products of human LDL.

Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF; DCCT/EDIC Research Group.

J Lipid Res. 2003 Mar;44(3):487-93. Epub 2002 Dec 1.

49.

Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.

Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF; DCCT/EDIC Research Group.

Clin Immunol. 2002 Oct;105(1):81-92.

PMID:
12483997
50.

Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy.

Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G.

Diabetologia. 2002 Nov;45(11):1562-71. Epub 2002 Oct 12.

PMID:
12436340

Supplemental Content

Loading ...
Support Center